Eli Lilly and CompanyLLYNYSE
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank44
3Y CAGR-17.7%
5Y CAGR-40.0%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-17.7%/yr
Quarterly compound
5Y CAGR
-40.0%/yr
Recent acceleration
Percentile
P44
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.64% |
| Q3 2025 | 17.68% |
| Q2 2025 | 31.76% |
| Q1 2025 | -6.72% |
| Q4 2024 | 27.43% |
| Q3 2024 | 2.97% |
| Q2 2024 | 61.52% |
| Q1 2024 | -14.33% |
| Q4 2023 | -9.82% |
| Q3 2023 | 51.43% |
| Q2 2023 | 36.37% |
| Q1 2023 | -22.32% |
| Q4 2022 | 8.33% |
| Q3 2022 | 16.79% |
| Q2 2022 | -34.48% |
| Q1 2022 | 7.78% |
| Q4 2021 | 15.93% |
| Q3 2021 | 40.47% |
| Q2 2021 | -13.41% |
| Q1 2021 | -26.55% |
| Q4 2020 | 59.71% |
| Q3 2020 | 1.30% |
| Q2 2020 | -15.63% |
| Q1 2020 | 8.96% |
| Q4 2019 | 2.77% |
| Q3 2019 | -0.79% |
| Q2 2019 | 24.67% |
| Q1 2019 | -21.01% |
| Q4 2018 | 8.06% |
| Q3 2018 | -10.34% |
| Q2 2018 | 17.03% |
| Q1 2018 | 83.34% |
| Q4 2017 | -36.85% |
| Q3 2017 | -7.41% |
| Q2 2017 | 17.61% |
| Q1 2017 | 6.05% |
| Q4 2016 | 6.55% |
| Q3 2016 | 0.78% |
| Q2 2016 | 15.83% |
| Q1 2016 | 13.90% |